Lutetium-177 Treatment Shows Positive Results

Rosatom, Russia's State Nuclear Energy Corporation, announced positive results from lutetium-177 treatment applied to patients with prostate cancer. The substance containing lutetium-177, used in the treatment of neuroendocrine tumors and prostate cancer, was developed using technology applied by the Nuclear Reactors Research Institute, which is part of Rosatom's research division. The radiopharmaceutical in question passed all stages of quality control. The treatment applied at the Federal Radiology and Oncology Research and Clinical Center (FRCCRO) under Russia's Federal Medical and Biological Agency is administered by intravenous injection of the drug after ensuring the patient has experienced no adverse effects. The medication, administered every two months, proved effective according to Pyotr Sychev, Head of the Nuclear Medicine Center and radiologist at FRCCRO, and no adverse effects were observed in any of the patients. Rosatom holds the distinction of being the only organization in the world capable of producing all types of the lutetium-177 isotope. Additionally, the lutetium-177 medical isotope has been supplied to Brazil since 2021. Source